Loading study record…
This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of community-based HIV prevention and treatment, HCV treatment, STI treatment, and opioid use disorder (OUD) prevention and treatment, medication for opioid use disorder (MOUD) service cascades of care.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-09-21
What this record can show
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
This 5-year Hybrid Type 1 Effectiveness-Implementation RCT trial compares two models of linking and retaining individuals recently released from justice involvement to the continuum of community-based HIV and OUD prevention and treatment (MOUD) service cascades of care. A significant innovation of this RCT is that it will be delivered within 4 communities where coalition infrastructures have been established as part of the Justice Community Opioid Innovation Network (JCOIN) studies, a National Institute on Drug Abuse (NIDA)-funded Cooperative Agreement initiative to mitigate the impact criminal justice (CJ)-involved individuals with OUD are having on local communities, and the investigators will be able to build on that existing infrastructure. Specifically, up to 960 CJ-involved individuals will be recruited across 2 CT (New London/Middlesex Counties and Windham/Tolland/New Haven/Hartford Counties) \& 2 Texas (Dallas and Tarrant Counties) high risk communities. HIV status will be assessed via rapid testing at initial point of contact. Participants will be randomized to receive at post-release either: a) a Patient Navigator (PN) system for care, wherein navigators will assist linking study participants to appropriate community service providers (e.g., OUD/SUD treatment including MOUD, and HCV testing and treatment; those not living with HIV will be provided access to pre-exposure prophylaxis (PrEP) services, and those living with HIV will receive assistance with gaining initial or continued access to antiretroviral therapy (ART) services, or b) services delivered via a Mobile Health Unit (MHU) within the participants community where participants will receive PrEP/ART, MOUD, and harm reduction services on the MHU or assistance from a community health worker (CHW) in linking to appropriate community-based OUD and other medical and behavioral health providers. The interventions will last for 6 months post-release from custody. The focus of this study is the randomized controlled trial. Study objectives: Aim 1 (Intervention Effectiveness) Primary: To compare the effectiveness of PN vs. MHU service delivery on participant length of time to initiating post-release PrEP (prevention)/ART (treatment) medication within 6 months following release from justice involvement. Secondary outcomes will examine the continuum of PrEP and HIV care outcomes, including (but not limited to) the following additional HIV-related measures: viral suppression for people living with HIV (PLH), PrEP adherence, HIV risk behaviors; HCV Measures: HCV testing \& linkage to treatment. Importantly, the investigators will also assess OUD and Substance Use Disorders (SUD)-related measures: OUD/SUD diagnoses, MOUD prescription receipt \& retention, opioid \& stimulant use, and overdose incidents. Other outcomes of interest include sexually transmitted infection (STI) incidence; and primary medical care appointments. Aim 2 (Implementation): To evaluate Patient Navigation (PN ) and Mobile Health Unit (MHU) feasibility, acceptability, and costs. Primary implementation outcomes include feasibility (health care utilization impact among released individuals, contributions of interagency workgroup members on outcomes); acceptability (participant satisfaction, perceived usefulness); sustainment (continued utilization), and costs required to implement and sustain the approaches as well as to scale-up in additional communities. Additional outcomes will examine the broader impact on community health care including other health services accessed, expanded OUD services, and common barriers (e.g., stigma) to service access across the community provider spectrum. The investigators will also assess cost offsets and effectiveness of the service delivery models on the cascade outcomes. A Persons Who Inject Drugs (PWID) sub-study will focus on gaining insight into participant and social context (inner and outer) factors associated with the effectiveness outcomes. Note: The study sample size was revised from 864 to 538 participants following identification of an error in the original power analysis, which incorrectly used HIV-positive initiation rates to estimate the overall effect size. A revised power analysis was conducted, and the updated sample size was reviewed and approved by the Data and Safety Monitoring Board (DSMB) during its August 2023 review.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
Source-reported results
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Restricted mean survival was used to reflect the number of days a person was without medication. Measured by self-reported initiation within 6-months. ART initiation will be measured as the date of self-reported initiation within the 6-month intervention period.
Population: Participants living with HIV
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 15 | 51 | 26.79 to 75.21 |
| Mobile Health Unit | 18 | 54.9 | 31.74 to 78.14 |
Restricted mean survival was used to reflect the number of days a person was without medication. Measured by self-reported initiation within 6-months. PrEP initiation will be measured as the date of self-reported initiation within the 6-month intervention period.
Eligibility
primary outcomes
Time frame: From the day of release/randomization to initiation of ART up to 6 months
Restricted mean survival was used to reflect the number of days a person was without medication. Measured by self-reported initiation within 6-months. ART initiation will be measured as the date of self-reported initiation within the 6-month intervention period.
Time frame: From the day of release/randomization to initiation of PrEP up to 6 months
Restricted mean survival was used to reflect the number of days a person was without medication. Measured by self-reported initiation within 6-months. PrEP initiation will be measured as the date of self-reported initiation within the 6-month intervention period.
secondary outcomes
Time frame: From the day of release/randomization to initiation of PrEP up to 6 months
The proportion of participants who initiate PrEP, of those who are not living with HIV, will be assessed via self-report and through confirmation with community provider
Time frame: 6 months
Proportion of participants prescribed PrEP at end of intervention via self-report and through confirmation with community provider
Time frame: 6 months
For participants who initiate PrEP, adherence will be assessed by self-reported PrEP adherence via Visual Analog Scale (VAS), 0-100, higher scores mean better adherence. 80% or greater on the VAS scale was considered adherent.
Time frame: Baseline and 12 months
Change in HIV status for participants testing negative using rapid point of care (POC) via Orasure tests at baseline that have a follow-up reactive HIV point of care test
Time frame: 6 months
For PLH, adherence to ART treatment will be assessed by self-reported ART adherence via Visual Analog Scale (VAS) 0-100, higher scores mean better adherence. 80% or greater on the VAS scale was considered adherent.
Time frame: 6 months
For PLH, HIV viral suppression, for those with HIV at time of randomization: the percent who maintain or achieve HIV viral load \< 200 copies/mL at 6 months
Time frame: from baseline up to 6 months
Changes in injection and sexual risk behaviors, a summary item from Dr. Springer's HIV Risk Behavior tool created for NIDA Seek, Test, Treat, and Retain (STTR) will be used to assess sharing of injection equipment and other drug and sexual risk behaviors
Time frame: from baseline up to 6 months
other outcomes
Time frame: 6 months
For participants who initiate PrEP, adherence will be measured by DBS testing (Orasure, Inc.) and defined as a tenofovirdisoproxil diphosphate (TFV-DP) level \>700 fmol/punch at 6 months, reflecting cumulative dosing over 6-8 weeks and consistent with 4 or more doses of PrEP per week.
Time frame: 6 months
For participants who initiate PrEP, adherence will be assessed by TFV-DP urine testing, which measures recent (past 48 hour) dosing (Orasure, Inc.)
Time frame: up to 6 months
For participants who initiate PrEP, the proportion who are adherent based on continuous PrEP prescription refill will be assessed by date of prescription refill and number of pills per refill, via pharmacy data.
Time frame: up to 6 months
Retention in PrEP care defined as attending 2 or more visits in 6 months post-release will be assessed via self-report and through confirmation with community provider
Time frame: 6 months
For participants living with HIV (PLH), adherence to ART treatment measured via the dry blood spot for TFV-DP, level \>700 fmol/punch at 6 months
Time frame: 6 months
For PLH, adherence to ART treatment measured via urine testing for TFV-DP based regimens.
Time frame: up to 6 months
For participants who are prescribed ART, the proportion who are adherent based on continuous ART prescription refill will be assessed by date of prescription refill and number of pills per refill, via pharmacy data.
Time frame: up to 6 months
For PLH, retention in HIV ART care: defined as attending 2 or more visits in 6 months post-release will be assessed via selfreport and through confirmation with community provider
Time frame: at baseline
Publications
No exact PMID-linked public article is currently readable locally.
Population: Participants at risk for HIV who meet full study criteria.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 295 | 178.83 | 175.75 to 181.91 |
| Mobile Health Unit | 306 | 172.53 | 167.87 to 177.19 |
The proportion of participants who initiate PrEP, of those who are not living with HIV, will be assessed via self-report and through confirmation with community provider
Population: Participants at risk for HIV who meet full study criteria.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 288 | 7 | - |
| Mobile Health Unit | 280 | 22 | - |
Proportion of participants prescribed PrEP at end of intervention via self-report and through confirmation with community provider
Population: Persons at risk for HIV. Meeting all study eligibility
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 288 | 7 | - |
| Mobile Health Unit | 280 | 22 | - |
For participants who initiate PrEP, adherence will be assessed by self-reported PrEP adherence via Visual Analog Scale (VAS), 0-100, higher scores mean better adherence. 80% or greater on the VAS scale was considered adherent.
Population: Persons at risk for HIV who initiated PrEP and attended month 6 interview.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 4 | 2 | - |
| Mobile Health Unit | 14 | 7 | - |
Change in HIV status for participants testing negative using rapid point of care (POC) via Orasure tests at baseline that have a follow-up reactive HIV point of care test
Population: Participants who started PrEP, who meet full study criteria, and attended Month 6 study visit.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 280 | 1 | - |
| Mobile Health Unit | 288 | 0 | - |
For PLH, adherence to ART treatment will be assessed by self-reported ART adherence via Visual Analog Scale (VAS) 0-100, higher scores mean better adherence. 80% or greater on the VAS scale was considered adherent.
Population: Participants living with HIV who completed Month 6 study visit
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 12 | 9 | - |
| Mobile Health Unit | 13 | 13 | - |
For PLH, HIV viral suppression, for those with HIV at time of randomization: the percent who maintain or achieve HIV viral load \< 200 copies/mL at 6 months
Population: For participants living with HIV who had HIV viral load recorded in their medical records.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 9 | 6 | - |
| Mobile Health Unit | 9 | 9 | - |
Changes in injection and sexual risk behaviors, a summary item from Dr. Springer's HIV Risk Behavior tool created for NIDA Seek, Test, Treat, and Retain (STTR) will be used to assess sharing of injection equipment and other drug and sexual risk behaviors
Population: Of those who met full criteria for the study and attended Month 6 study visit.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 188 | 74 | - |
| Mobile Health Unit | 190 | 84 | - |
Changes in injection and sexual risk behaviors, a summary item from Dr. Springer's HIV Risk Behavior tool created for NIDA Seek, Test, Treat, and Retain (STTR) will be used to assess sharing of injection equipment and other drug and sexual risk behaviors
Population: Of those who met full criteria for the study and attended Month 6 study visit.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 188 | 5 | - |
| Mobile Health Unit | 190 | 3 | - |
Type of opioids used (not as prescribed) will be assessed by the Texas Christian University Drug Screen 5.
Population: Participants meeting criteria for the study and attended month 6 visit.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 188 | 14 | - |
| Mobile Health Unit | 190 | 10 | - |
| Patient Navigator | 188 | 20 | - |
| Mobile Health Unit | 190 | 19 | - |
| Patient Navigator | 188 | 3 | - |
| Mobile Health Unit | 190 | 6 | - |
The mean days of opioid use by self-report via the timeline followback (TLFB).
Population: Participants meeting criteria for the study
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 295 | 20 | 45 |
| Mobile Health Unit | 306 | 24 | 48 |
Substance use treatment participation will be collected via self-report. Treatments include detoxification, residential treatment, and medication treatments.
Population: Participants meeting criteria for the study and attended month 6 visit
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 188 | 56 | - |
| Mobile Health Unit | 190 | 49 | - |
Types of other substances used (e.g. stimulant, benzodiazepine, marijuana, synthetic cannabinoids, and alcohol) not as prescribed will be assessed self-reported via Texas Christian University Drug Screen 5
Population: Participants meeting criteria for the study and attended month 6 visit
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 188 | 18 | - |
| Mobile Health Unit | 190 | 19 | - |
| Patient Navigator | 188 | 8 | - |
| Mobile Health Unit | 190 | 7 | - |
| Patient Navigator | 188 | 31 | - |
| Mobile Health Unit | 190 | 29 | - |
| Patient Navigator | 188 | 26 | - |
| Mobile Health Unit | 190 | 27 | - |
| Patient Navigator | 188 | 0 | - |
| Mobile Health Unit | 190 | 2 | - |
| Patient Navigator | 188 | 0 | - |
| Mobile Health Unit | 190 | 3 | - |
| Patient Navigator | 188 | 0 | - |
| Mobile Health Unit | 190 | 1 | - |
Occurrence of non-fatal and fatal substance use related overdoses, through self-report, confirmation with medical providers, and mortality index data
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 295 | 10 | - |
| Mobile Health Unit | 306 | 23 | - |
| Patient Navigator | 295 | 3 | - |
| Mobile Health Unit | 306 | 2 | - |
Occurrence of non-fatal and fatal substance use related overdoses, through self-report, confirmation with medical providers, and mortality index data
Population: All participants who were still enrolled in the study at Month 6
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Patient Navigator | 270 | 10 | - |
| Mobile Health Unit | 279 | 17 | - |
| Patient Navigator | 270 | 0 | - |
| Mobile Health Unit | 279 | 0 | - |
For participants who initiate PrEP, adherence will be measured by DBS testing (Orasure, Inc.) and defined as a tenofovirdisoproxil diphosphate (TFV-DP) level \>700 fmol/punch at 6 months, reflecting cumulative dosing over 6-8 weeks and consistent with 4 or more doses of PrEP per week.
For participants who initiate PrEP, adherence will be assessed by TFV-DP urine testing, which measures recent (past 48 hour) dosing (Orasure, Inc.)
For participants who initiate PrEP, the proportion who are adherent based on continuous PrEP prescription refill will be assessed by date of prescription refill and number of pills per refill, via pharmacy data.
Retention in PrEP care defined as attending 2 or more visits in 6 months post-release will be assessed via self-report and through confirmation with community provider
For participants living with HIV (PLH), adherence to ART treatment measured via the dry blood spot for TFV-DP, level \>700 fmol/punch at 6 months
For PLH, adherence to ART treatment measured via urine testing for TFV-DP based regimens.
For participants who are prescribed ART, the proportion who are adherent based on continuous ART prescription refill will be assessed by date of prescription refill and number of pills per refill, via pharmacy data.
For PLH, retention in HIV ART care: defined as attending 2 or more visits in 6 months post-release will be assessed via selfreport and through confirmation with community provider
The proportion who test positive on rapid POC Hepatitis C virus (HCV) test with confirmatory reflex HCV viral load at baseline
The proportion who test positive on rapid POC HCV test with confirmatory HCV viral load at 6 months
Time to linked appointment for HCV treatment during the 6 month intervention will be assessed via self-report and through confirmation with community provider
Time to HCV direct acting antiviral treatment (DAAs) during the 6 month will be assessed via self-report VAS
HCV direct acting antiviral treatment (DAAs) during the 6 month will be assessed via prescription refill data
Initiation of HCV direct acting antiviral treatment (DAAs) during the 6 month will be assessed via confirmation with community provider
The proportion of participants prescribed DAAs who complete treatment will be assessed via self-report at 6 months
The proportion of participants prescribed DAAs who complete treatment will be assessed via prescription refill data at 6 months
The proportion of participants prescribed DAAs, who complete treatment will be assessed via confirmation with community provider at 6 months
The proportion of participants who achieve SVR at week 12 upon completion of DAA prescription medication, assessed as undetectable HCV viral load.
The proportion of participants, of those that achieve HCV SVR, that are re-infected with HCV at 12 months, via reactive rapid HCV POC test result
Opioid use (not as prescribed) will be assessed by the proportion of monthly urine samples negative vs. positive/missing
Number of days of opioid use, not as prescribed, will be assessed using the timeline follow back (TLFB) method
Time to linked appointment for MOUD treatment during the 6 month intervention will be assessed via self-report
Time to linked appointment for MOUD treatment during the 6 month intervention will be assessed via confirmation with community provider
Retention on MOUD type and dose of MOUD via confirmation from community provider
Retention on MOUD, using the Justice Community Opioid Innovation Network (JCOIN) instrument via self-reported type and dose of MOUD
Use of other substances (e.g. stimulant, benzodiazepine, methylenedioxymethamphetamine, marijuana, and alcohol) not as prescribed, will be assessed by the proportion of monthly urine samples negative vs. positive/missing
| Milestone | Patient Navigator | Mobile Health Unit |
|---|---|---|
| STARTED | 295 | 306 |
| COMPLETED | 295 | 306 |
| NOT COMPLETED | 0 | 0 |
| Event | System | Groups: affected / at risk |
|---|---|---|
| pulmonary embolism | Cardiac disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 2 / 306 |
| Cardio vasular disease | Cardiac disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| irregular heartbeat | Cardiac disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| heart failure | Cardiac disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| pericarditis | Cardiac disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 0 / 306 |
| stroke | Cardiac disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| diabetic ketoacidosis | Endocrine disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 2 / 306 |
| hyperthyroidism | Endocrine disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| foreign body ingestion | Gastrointestinal disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 0 / 306 |
| esophagitis | Gastrointestinal disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| dysphagia | Gastrointestinal disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| Chest/Abdominal pain | General disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| Headaches | General disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| Cholecystitis | Hepatobiliary disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 0 / 306 |
| Infection - skeletal | Infections and infestations | Patient Navigator: 1 / 295 · Mobile Health Unit: 3 / 306 |
| Infection - skin | Infections and infestations | Patient Navigator: 3 / 295 · Mobile Health Unit: 4 / 306 |
| Fatal overdose | Injury, poisoning and procedural complications | Patient Navigator: 3 / 295 · Mobile Health Unit: 2 / 306 |
| Non-fatal overdose | Injury, poisoning and procedural complications | Patient Navigator: 4 / 295 · Mobile Health Unit: 2 / 306 |
| Substance use withdrawal | Injury, poisoning and procedural complications | Patient Navigator: 0 / 295 · Mobile Health Unit: 4 / 306 |
| Gun shot wound | Injury, poisoning and procedural complications | Patient Navigator: 1 / 295 · Mobile Health Unit: 1 / 306 |
| Motor vehicle accident | Injury, poisoning and procedural complications | Patient Navigator: 2 / 295 · Mobile Health Unit: 1 / 306 |
| Fracture | Injury, poisoning and procedural complications | Patient Navigator: 2 / 295 · Mobile Health Unit: 3 / 306 |
| General injury (falls and fights) | Injury, poisoning and procedural complications | Patient Navigator: 2 / 295 · Mobile Health Unit: 4 / 306 |
| Spinal injury after fall | Injury, poisoning and procedural complications | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| Unknown cause of death | Injury, poisoning and procedural complications | Patient Navigator: 2 / 295 · Mobile Health Unit: 2 / 306 |
| Low potassium | Metabolism and nutrition disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 0 / 306 |
| seizure-like symptoms | Nervous system disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| epilepsy | Nervous system disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 2 / 306 |
| Child birth | Pregnancy, puerperium and perinatal conditions | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| Mental health crisis | Psychiatric disorders | Patient Navigator: 2 / 295 · Mobile Health Unit: 2 / 306 |
| Suicidal ideation/attempt non-fatal | Psychiatric disorders | Patient Navigator: 2 / 295 · Mobile Health Unit: 2 / 306 |
| Kidney issues | Renal and urinary disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 0 / 306 |
| Erectile pain | Reproductive system and breast disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| COPD | Respiratory, thoracic and mediastinal disorders | Patient Navigator: 0 / 295 · Mobile Health Unit: 1 / 306 |
| pneumonia | Respiratory, thoracic and mediastinal disorders | Patient Navigator: 4 / 295 · Mobile Health Unit: 2 / 306 |
| Rash | Skin and subcutaneous tissue disorders | Patient Navigator: 1 / 295 · Mobile Health Unit: 0 / 306 |
| Planned surgery | Surgical and medical procedures | Patient Navigator: 1 / 295 · Mobile Health Unit: 2 / 306 |
| Event | System | Groups: affected / at risk |
|---|---|---|
| Nonfatal overdose | Injury, poisoning and procedural complications | Patient Navigator: 19 / 295 · Mobile Health Unit: 34 / 306 |
| Incarceration/reincarceration | Social circumstances | Patient Navigator: 108 / 295 · Mobile Health Unit: 110 / 306 |
Changes in injection and sexual risk behaviors, a summary item from Dr. Springer's HIV Risk Behavior tool created for NIDA Seek, Test, Treat, and Retain (STTR) will be used to assess sharing of injection equipment and other drug and sexual risk behaviors
Time frame: 6 months
Type of opioids used (not as prescribed) will be assessed by the Texas Christian University Drug Screen 5.
Time frame: 6 months
The mean days of opioid use by self-report via the timeline followback (TLFB).
Time frame: 6 months
Substance use treatment participation will be collected via self-report. Treatments include detoxification, residential treatment, and medication treatments.
Time frame: 6 months
Types of other substances used (e.g. stimulant, benzodiazepine, marijuana, synthetic cannabinoids, and alcohol) not as prescribed will be assessed self-reported via Texas Christian University Drug Screen 5
Time frame: 6 months
Occurrence of non-fatal and fatal substance use related overdoses, through self-report, confirmation with medical providers, and mortality index data
Time frame: From Month 6 to Month 12
Occurrence of non-fatal and fatal substance use related overdoses, through self-report, confirmation with medical providers, and mortality index data
The proportion who test positive on rapid POC Hepatitis C virus (HCV) test with confirmatory reflex HCV viral load at baseline
Time frame: 6 months
The proportion who test positive on rapid POC HCV test with confirmatory HCV viral load at 6 months
Time frame: Day of release/randomization to appointment time up to 6 months
Time to linked appointment for HCV treatment during the 6 month intervention will be assessed via self-report and through confirmation with community provider
Time frame: From baseline to reported treatment up to 6 months
Time to HCV direct acting antiviral treatment (DAAs) during the 6 month will be assessed via self-report VAS
Time frame: up to 6 months
HCV direct acting antiviral treatment (DAAs) during the 6 month will be assessed via prescription refill data
Time frame: up to 6 months
Initiation of HCV direct acting antiviral treatment (DAAs) during the 6 month will be assessed via confirmation with community provider
Time frame: 6 months
The proportion of participants prescribed DAAs who complete treatment will be assessed via self-report at 6 months
Time frame: 6 months
The proportion of participants prescribed DAAs who complete treatment will be assessed via prescription refill data at 6 months
Time frame: 6 months
The proportion of participants prescribed DAAs, who complete treatment will be assessed via confirmation with community provider at 6 months
Time frame: up to 6 months
The proportion of participants who achieve SVR at week 12 upon completion of DAA prescription medication, assessed as undetectable HCV viral load.
Time frame: 12 months
The proportion of participants, of those that achieve HCV SVR, that are re-infected with HCV at 12 months, via reactive rapid HCV POC test result
Time frame: 6 months
Opioid use (not as prescribed) will be assessed by the proportion of monthly urine samples negative vs. positive/missing
Time frame: 6 months
Number of days of opioid use, not as prescribed, will be assessed using the timeline follow back (TLFB) method
Time frame: From day of release/randomization to appointment for MOUD up to 6 months
Time to linked appointment for MOUD treatment during the 6 month intervention will be assessed via self-report
Time frame: From day of release/randomization to appointment for MOUD up to 6 months
Time to linked appointment for MOUD treatment during the 6 month intervention will be assessed via confirmation with community provider
Time frame: up to 6 months
Retention on MOUD type and dose of MOUD via confirmation from community provider
Time frame: up to 6 months
Retention on MOUD, using the Justice Community Opioid Innovation Network (JCOIN) instrument via self-reported type and dose of MOUD
Time frame: 6 months
Use of other substances (e.g. stimulant, benzodiazepine, methylenedioxymethamphetamine, marijuana, and alcohol) not as prescribed, will be assessed by the proportion of monthly urine samples negative vs. positive/missing